Market Place
Sourcing Support
BriaCell 2024 SABCS® Poster Highlights Bria-IMT™ Benefits
13 Dec 2024 //
GLOBENEWSWIRE
BriaCell Closes $5.5M Public Offering Successfully
13 Dec 2024 //
GLOBENEWSWIRE
BriaCell Presents Data in Metastatic Breast Cancer at SABCS
11 Dec 2024 //
GLOBENEWSWIRE
BriaCell Therapeutics Announces Proposed Public Offering
11 Dec 2024 //
GLOBENEWSWIRE
BriaCell Therapeutics Prices $5.5 Million Public Offering
11 Dec 2024 //
GLOBENEWSWIRE
BriaCell to Present SABCS® Spotlight Poster on Breast Cancer
26 Nov 2024 //
GLOBENEWSWIRE
BriaCell Provides Update to its Board of Directors
25 Nov 2024 //
GLOBENEWSWIRE
BriaCell Doses First Patient in Metastatic Breast Cancer Study
21 Nov 2024 //
GLOBENEWSWIRE
BriaCell Showcases Off-the-Shelf Immunotherapy at SITC 2024
08 Nov 2024 //
GLOBENEWSWIRE
BriaCell’s Overall Survival Data Selected for SABCS 2024 Spotlight
04 Nov 2024 //
GLOBENEWSWIRE
BriaCell Reports Survival Data For Metastatic Breast Cancer
22 Oct 2024 //
GLOBENEWSWIRE
BriaCell Provides Phase 3 Clinical Update In Metastatic Breast Cancer
15 Oct 2024 //
GLOBENEWSWIRE
BriaCell Therapeutics Announces Closing of $5 Million Offering
03 Oct 2024 //
GLOBENEWSWIRE
BriaCell Therapeutics Announces $5 Million Offering
01 Oct 2024 //
GLOBENEWSWIRE
BriaCell Announces FDA-Authorized Expanded Access Policy
18 Sep 2024 //
GLOBENEWSWIRE
BriaCell Therapeutics Announces Closing of $8.5 Million Offering
12 Sep 2024 //
GLOBENEWSWIRE
BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer
11 Sep 2024 //
GLOBENEWSWIRE
BriaCell Therapeutics Announces $8.5 Million Offering
11 Sep 2024 //
GLOBENEWSWIRE
BriaCell Announces Positive FDA Pre-IND Meeting Results for Cancer
10 Sep 2024 //
GLOBENEWSWIRE
BriaCell Announces Presentation At SITC Annual Meeting
09 Sep 2024 //
GLOBENEWSWIRE
BriaCell Reports Quadrupled PFS In Metastatic Breast Cancer Patient
18 Jul 2024 //
GLOBENEWSWIRE
BriaCell Presents Clinical Efficacy Data at ASCO 2024
03 Jun 2024 //
GLOBENEWSWIRE
BriaCell Starts First-In-Human Bria-OTS„ Study In Metastatic Breast Cancer
30 May 2024 //
GLOBENEWSWIRE
Briacell Pfs Doubled Asco Data: Clinical Benefit In Ovarian Cancer
24 May 2024 //
GLOBENEWSWIRE
BriaCell Announces $5M Registered Direct Offering Closing
17 May 2024 //
GLOBENEWSWIRE
BriaCell Prices $5M Registered Direct Offering
15 May 2024 //
GLOBENEWSWIRE
BriaCell Confirms Strong Anti-Cancer Activity for Bria-OTS+ and Bria-PROS+
10 Apr 2024 //
GLOBENEWSWIRE
BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis
06 Mar 2024 //
GLOBENEWSWIRE
BriaCell Provides Update on Alleged Illegal Trading of Public Securities
27 Feb 2024 //
GLOBENEWSWIRE
BriaCell Announces Strong Clinical Data in Breast Cancer Patients
07 Feb 2024 //
GLOBENEWSWIRE
BriaCell Announces Lead Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing
06 Feb 2024 //
GLOBENEWSWIRE
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
30 Jan 2024 //
GLOBENEWSWIRE
BriaCell Reports 71% Nervous System Response Rate in Breast Cancer Patients
28 Dec 2023 //
GLOBENEWSWIRE
BriaCell Reports Clinical Benefit in ADC Refractory Patient Subset
20 Dec 2023 //
GLOBENEWSWIRE
BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells
06 Dec 2023 //
GLOBENEWSWIRE
BriaCell Highlights Benefit Data in Advanced Metastatic Breast Cancer
06 Dec 2023 //
GLOBENEWSWIRE
BriaCell Records Responder with Improvement of Eye-Bulging Metastatic Tumor
30 Nov 2023 //
GLOBENEWSWIRE
BriaCell Reports Activity of Breast and Prostate Cancer Immunotherapies
03 Nov 2023 //
GLOBENEWSWIRE
BriaCell Forms Medical Advisory Board of Distinguished Breast Cancer Specialists
25 Oct 2023 //
GLOBENEWSWIRE
BriaCell is Leading the Fight with its Innovative Technology
20 Oct 2023 //
GLOBENEWSWIRE
BriaCell Announces Presentations at SITC
18 Oct 2023 //
GLOBENEWSWIRE
BriaCell To Host Virtual Key Opinion Leader Event on Bria-IMT
11 Oct 2023 //
GLOBENEWSWIRE
BriaCell Partners with NYCBS for Phase 3 Study of Bria-IMT in Breast Cancer
04 Oct 2023 //
GLOBENEWSWIRE
BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT
03 Oct 2023 //
GLOBENEWSWIRE
BriaCell Reports Patient Survival in Advanced Metastatic Breast Cancer
08 Sep 2023 //
GLOBENEWSWIRE
BriaCell Announces Closing of Plan of Arrangement Spinning Out BriaPro
31 Aug 2023 //
GLOBENEWSWIRE
BriaCell Receives Court Approval for the Share Arrangement Spinning Out BriaPro
25 Aug 2023 //
GLOBENEWSWIRE
BriaCell Therapeutics Corp. Announces Voting Results From Special Meeting
18 Aug 2023 //
GLOBENEWSWIRE
BriaCell Awarded National Cancer Institute Grant for Bria-OTS Immunotherapy
16 Aug 2023 //
GLOBENEWSWIRE
BriaCell Enters Agreement for the Spin Out of BriaPro Therapeutics Corp.
25 May 2023 //
GLOBENEWSWIRE
BriaCell Closes $4 Million Strategic Investment by Prevail Partners
19 May 2023 //
GLOBENEWSWIRE
BriaCell Announces $4 M Investment & Clinical Alliance with Prevail Partners
15 May 2023 //
GLOBENEWSWIRE
BriaCell Announces Intention to Spin-Out Certain Pre-Clinical Assets
30 Mar 2023 //
GLOBENEWSWIRE
BriaCell spins out new company with a couple preclinical meds
30 Mar 2023 //
FIERCE BIOTECH
BriaCell to Present Data in Advanced Metastatic Breast Cancer at AACR
15 Mar 2023 //
GLOBENEWSWIRE
BriaCell Reports Positive Survival Data in Advanced Metastatic Breast Cancer
23 Feb 2023 //
GLOBENEWSWIRE
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
08 Feb 2023 //
GLOBENEWSWIRE
BriaCell CEO Letter to Shareholders
24 Jan 2023 //
GLOBENEWSWIRE
BriaCell to Investigate Alleged Illegal Trading of Public Securities
23 Jan 2023 //
GLOBENEWSWIRE
BriaCell Announces Positive End of Phase II Meeting with the FDA for Bria-IMT
18 Jan 2023 //
GLOBENEWSWIRE
